Southeast Asset Advisors Inc. purchased a new position in shares of Hill-Rom Holdings, Inc. (NYSE:HRC) in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund purchased 8,461 shares of the medical technology company’s stock, valued at approximately $885,000.
Other hedge funds have also recently added to or reduced their stakes in the company. State Board of Administration of Florida Retirement System boosted its stake in shares of Hill-Rom by 0.6% during the 1st quarter. State Board of Administration of Florida Retirement System now owns 85,337 shares of the medical technology company’s stock worth $9,034,000 after purchasing an additional 510 shares during the period. BB&T Securities LLC purchased a new position in shares of Hill-Rom during the 2nd quarter worth about $322,000. Martingale Asset Management L P boosted its stake in shares of Hill-Rom by 5.4% during the 1st quarter. Martingale Asset Management L P now owns 496,990 shares of the medical technology company’s stock worth $52,612,000 after purchasing an additional 25,415 shares during the period. Parametric Portfolio Associates LLC boosted its stake in shares of Hill-Rom by 10.5% during the 1st quarter. Parametric Portfolio Associates LLC now owns 149,080 shares of the medical technology company’s stock worth $15,782,000 after purchasing an additional 14,223 shares during the period. Finally, Campbell & CO Investment Adviser LLC lifted its holdings in Hill-Rom by 142.2% during the 2nd quarter. Campbell & CO Investment Adviser LLC now owns 5,812 shares of the medical technology company’s stock valued at $608,000 after buying an additional 3,412 shares in the last quarter. 82.67% of the stock is owned by hedge funds and other institutional investors.
In other news, SVP Paul Sherwood Johnson sold 6,470 shares of the business’s stock in a transaction dated Wednesday, August 14th. The shares were sold at an average price of $104.26, for a total value of $674,562.20. Following the completion of the sale, the senior vice president now owns 8,215 shares in the company, valued at approximately $856,495.90. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Deborah Rasin sold 5,500 shares of the business’s stock in a transaction dated Wednesday, August 7th. The shares were sold at an average price of $103.00, for a total transaction of $566,500.00. Following the completion of the sale, the senior vice president now owns 20,939 shares of the company’s stock, valued at approximately $2,156,717. The disclosure for this sale can be found here. Insiders own 0.73% of the company’s stock.
Hill-Rom (NYSE:HRC) last announced its quarterly earnings data on Friday, August 2nd. The medical technology company reported $1.23 earnings per share for the quarter, beating analysts’ consensus estimates of $1.21 by $0.02. Hill-Rom had a net margin of 7.45% and a return on equity of 21.26%. The company had revenue of $726.80 million during the quarter, compared to analyst estimates of $718.08 million. During the same quarter last year, the business posted $1.15 EPS. The firm’s revenue for the quarter was up 2.6% on a year-over-year basis. On average, equities analysts forecast that Hill-Rom Holdings, Inc. will post 5.05 earnings per share for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Monday, September 30th. Stockholders of record on Friday, September 20th will be issued a $0.21 dividend. The ex-dividend date is Thursday, September 19th. This represents a $0.84 annualized dividend and a dividend yield of 0.81%. Hill-Rom’s dividend payout ratio is currently 17.68%.
HRC has been the subject of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $125.00 price objective on shares of Hill-Rom in a report on Tuesday, August 6th. KeyCorp lifted their price objective on shares of Hill-Rom from $114.00 to $125.00 and gave the company an “overweight” rating in a report on Monday, August 5th. Zacks Investment Research upgraded shares of Hill-Rom from a “hold” rating to a “buy” rating and set a $103.00 price objective for the company in a report on Thursday, June 6th. Barclays lifted their price objective on shares of Hill-Rom from $108.00 to $116.00 and gave the company an “equal weight” rating in a report on Tuesday, August 6th. Finally, ValuEngine lowered shares of Hill-Rom from a “buy” rating to a “hold” rating in a report on Thursday, August 1st. Three investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $112.43.
Hill-Rom Holdings, Inc operates as a medical technology company worldwide. It operates in three segments: Patient Support Systems, Front Line Care, and Surgical Solutions. The company offers medical surgical beds, intensive care unit beds, and bariatric patient beds, lifts and other patient mobility devices, non-invasive therapeutic products and surfaces, and information technologies and software solutions; and medical equipment management services, as well as sells equipment service contracts for its capital equipment.
Featured Article: Balance Sheet
Want to see what other hedge funds are holding HRC? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hill-Rom Holdings, Inc. (NYSE:HRC).
Receive News & Ratings for Hill-Rom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hill-Rom and related companies with MarketBeat.com's FREE daily email newsletter.